Results 111 to 120 of about 10,236,148 (357)
Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA.
, 1999 Oxidative stress plays a central role in the pathogenesis of Parkinson's disease (PD). L-DOPA, the gold standard in PD therapy, may paradoxically contribute to the progression of the disease because of its pro-oxidant properties.
Godi L. +12 more
core +1 more source
Inherited metabolic epilepsies–established diseases, new approaches
Epilepsia Open, EarlyView.Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley +1 more source
Neurobiology of Disease, 2009 Development of L-DOPA-induced dyskinesia (LID) remains a major problem in the long-term treatment of Parkinson's disease (PD). Sensitization to L-DOPA correlates with ectopic expression of D3 dopamine receptors in the striatum, implicating D3 receptors ...
Naomi P. Visanji +5 more
doaj +1 more source
Effects of L-Dopa and Dopamine D2 Agonists on Recollection and Familiarity in Idiopathic Nondementing Parkinson’s Disease [PDF]
, 2011 Idiopathic nondementing Parkinson’s disease (PD) is marked by progressive loss of dopaminergic neurons in the substantia nigra pars compacta and ventral tegmental area.
Edelstyn
core +1 more source
Ketogenic diet for infantile epileptic spasms
Epilepsia Open, EarlyView.Abstract Approximately half of all cases of Infantile Epileptic Spasms Syndrome (IESS) do not respond to vigabatrin and hormonal therapies. There is no clear consensus as to the second‐line therapy for IESS. Ketogenic diet (KD) has emerged as an effective treatment for certain drug‐resistant epilepsies and in many cases of IESS.
Morris H. Scantlebury +3 more
wiley +1 more source
PSD-95, une nouvelle protéine contrôlant les dyskinésies induites par la L-DOPA [PDF]
, 2013 Matthieu F. Bastide, Erwan Bézard
openalex +1 more source
L-Dopa and Brain Serotonin System Dysfunction
, 2015 L-dopa is used to treat the motor symptoms associated with Parkinson’s disease, a neurodegenerative movement disorder characterized by a loss of dopamine neurons.
Bryan Yamamoto +3 more
core +1 more source
Somatic cell reprogramming for Parkinson's disease treatment
Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley +1 more source
l-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or l-Dopa history
, 2015 In Parkinson’s disease, the efficacy of l-Dopa treatment changes over time, as dyskinesias emerge with previously beneficial doses. Using MitoPark mice, that models mitochondrial failure in dopamine (DA) neurons and mimics the progressive loss of ...
Cadet, Jean-Lud +8 more
core +1 more source
Hypervision Proton Surgery: The Future Direction of Proton Therapy
iNew Medicine, EarlyView.ABSTRACT Proton beams provide unique physical advantages characterized by a low entrance dose, negligible exit dose, and a sharp Bragg peak, which enable superior sparing of normal tissues and support safe dose escalation for improved tumor control. However, conventional photon‐based fractionation remains widely used in proton therapy, where prolonged ...
Li Li, Shuanghu Yuan
wiley +1 more source